Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The DISCOVER Trial (Diagnosis of Infection in Stem Cell Transplant Patients OVER Time) (DISCOVER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02804464
Recruitment Status : Active, not recruiting
First Posted : June 17, 2016
Last Update Posted : August 6, 2019
Sponsor:
Collaborator:
University of California, San Francisco
Information provided by (Responsible Party):
Karius, Inc.

Brief Summary:
Demonstrate that the Karius Infectious Disease Diagnostic Sequencing Assay performed on plasma can accurately detect the microbiologic etiology in febrile allogeneic stem-cell transplant patients when compared with standard clinical diagnostics

Condition or disease
Bone Marrow Transplant Infection

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The DISCOVER Trial (Diagnosis of Infection in Stem Cell Transplant Patients OVER Time)
Study Start Date : July 2016
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : September 2019



Primary Outcome Measures :
  1. Demonstrate that the Karius Infectious Disease Diagnostic Sequencing Assay performed on plasma can accurately detect the microbiologic etiology in febrile allogeneic stem-cell transplant patients when compared with standard clinical diagnostics. [ Time Frame: 7 days ]

Biospecimen Retention:   Samples With DNA
Plasma


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients who are being evaluated for a stem-cell transplant at the University of California, San Francisco Hospital will be eligible for this study.
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Patients who plan on undergoing an allogeneic stem cell transplant and are admitted to UCSF Medical Center.

Exclusion Criteria:

  • Inability to provide informed consent and comply with study-related procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02804464


Locations
Layout table for location information
United States, California
University of California, San Francisco
San Francisco, California, United States, 94143
Sponsors and Collaborators
Karius, Inc.
University of California, San Francisco
Investigators
Layout table for investigator information
Principal Investigator: Peter Chin-Hong, MD University of California, San Francisco

Layout table for additonal information
Responsible Party: Karius, Inc.
ClinicalTrials.gov Identifier: NCT02804464    
Other Study ID Numbers: 002-CL-01
First Posted: June 17, 2016    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases